Previous close | 9.51 |
Open | 9.67 |
Bid | 8.85 x 100 |
Ask | 8.96 x 100 |
Day's range | 8.85 - 9.67 |
52-week range | 1.93 - 9.69 |
Volume | |
Avg. volume | 205,770 |
Market cap | 471.536M |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
TScan Therapeutics ( NASDAQ:TCRX ) First Quarter 2024 Results Key Financial Results Revenue: US$566.0k (down 92% from...
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -28% and 84.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.